Isatin, a monoamine oxidase inhibitor, sensitizes resistant breast cancer cells to tamoxifen via MAO-A/HIF1α/MMPs modulation
- 10 December 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (12) , 6214-6227
Abstract
Isatin enhances the anticancer activity of tamoxifen in resistant breast cancer cells by inhibiting MAO-A, inducing apoptosis and overcoming drug resistance.Keywords
This publication has 49 references indexed in Scilit:
- The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissuesCancer Medicine, 2020
- Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cellsThe Prostate, 2019
- Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapyJournal of Neural Transmission, 2018
- Isatin, an endogenous nonpeptide biofactor: A review of its molecular targets, mechanisms of actions, and their biomedical implicationsBioFactors, 2018
- Monoamine oxidase A is highly expressed in classical Hodgkin lymphomaThe Journal of Pathology, 2017
- Emerging role of monoamine oxidase as a therapeutic target for cardiovascular diseaseCurrent Opinion in Pharmacology, 2017
- Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signalingJournal of Hepatology, 2014
- The Significance of Monoamine Oxidase-A Expression in High Grade Prostate CancerJournal of Urology, 2008
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate CancerJAMA, 1997